The major shift in medical cannabis over the past three years has not been which countries legalized it. It has been how patients actually reach their cannabis prescriber. In the United States, Germany, the United Kingdom, and Australia, the same pattern is playing out. Virtual consultations are replacing the in-person medical visit right before our eyes. Digital certifications and prescriptions rarely require an in person visit. Telemedicine has quietly become the default access route for medical cannabis worldwide and the data from the last two years makes the trend impossible to ignore.
The US Built the Blueprint Out of Necessity
The United States pioneered the telehealth-first model, but not by design. The Covid pandemic grew telemedicine usage at an unbelievable pace. Afterall, the US deemed cannabis dispensaries an essential business, which was absolutely surprising to many individuals. With cannabis still federally illegal, but legal for medical use in 40 states (as of mid-2025), operators faced a fragmented compliance environment from day one. Each state runs its own medical cannabis program. Each state has its own qualifying conditions list, its own physician licensing rules and its own patient registration requirements. Building a brick-and-mortar clinic network across that patchwork made no economic sense because telehealth did.
US platforms like MMJ.com now operate across 21 states, handling state-level compliance behind a single patient-facing experience. MMJ patients are able to schedule appointments with cannabis doctors via telemedicine for efficiency. The platform routes them to the right MMJ physician, documentation flow, and state registry behind the scenes. What started as a workaround for a fragmented regulatory environment turned out to be the structural foundation of the entire medical cannabis industry, accelerated by the pandemic-era expansion of telehealth flexibilities in 2020.
The telemedicine experience hides the complexity for patients. Someone applying for a medical marijuana card in Arkansas goes through a different qualifying pathway than someone applying in Texas, Pennsylvania, or Ohio, but neither patient has to learn those differences themselves. The MMJ platform absorbs the regulatory friction and streamlines the process, basically leaving the patient to simply wait for their medical card to be issued or arrive in the mail.
Telemedicine has become a dominant onboarding channel for new medical cannabis patients in many US state programs, and total active US medical cannabis patient enrollment has grown from roughly 678,000 in 2016 to around 3 million by 2020 (per a 2022 Annals of Internal Medicine analysis), with continued growth since.
Germany Ran the Experiment at Speed
Then Germany compressed the same evolution into about a year and a half.
On April 1, 2024, Germany’s new Medical Cannabis Act (MedCanG) removed cannabis from the country’s narcotics list. Medical doctors could suddenly prescribe it like any other medication, with no special permits and no quotas. The result was one of the fastest patient-access expansions in modern European healthcare. Many believe the other nations watched the USA as a test dummy, learning from what worked well and how it was not abused.
Between March 2024 and December 2025, German medical cannabis prescriptions surged roughly 3,300%, according to data published by Bloomwell, the country’s largest digital cannabis platform. Patient counts climbed from about 250,000 in April 2024 to nearly 900,000 by mid-2025. By the end of 2025, the German medical cannabis market was valued at around $997 million, up 155% year over year, large enough to make Germany the biggest patient market outside North America.
The driver was almost entirely through telemedicine and the ease of scheduling an appointment and speaking with a cannabis doctor within minutes. In some German states, more than 60% of rural patients relied solely on digital prescriptions. Telemedicine was the only access channel that could scale fast enough to absorb the demand the new law unlocked.
The UK Followed the Same Curve
The United Kingdom legalized medical cannabis in November 2018 but moved much more slowly. Restrictive NHS prescribing rules and a requirement that only specialist consultants could initiate prescriptions kept the patient count small for years. Private telehealth clinics eventually changed the trajectory of the UK’s growth.
Between 2022 and 2024, the volume of medical cannabis flower prescribed to UK patients rose 262%, from approximately 2,700 kilograms to over 10,000 kilograms, according to Home Office import records. Prescription counts more than doubled in a single year. By the end of 2025, the UK had an estimated 80,000 active medical cannabis patients accessing care through roughly 20 to 25 specialist clinics, the bulk of them telehealth-first operators (Releaf, Mamedica, Alternaleaf, Curaleaf Clinic, and others).
A vast majority of the United Kingdom’s medical cannabis prescriptions now flow through private channels, and the majority of those private prescriptions happen in telemedicine consultations.
Why the Same Model Won in Four Different Healthcare Systems
What stands out is how convergent the model is across very different countries. The US runs a fragmented private-insurance and state-by-state framework. Germany operates a public statutory health insurance system. The UK has the NHS alongside a parallel private market. Australia, where roughly one million individuals now use medicinal cannabis under the Therapeutic Goods Administration’s Special Access Scheme, has seen its own telehealth-driven boom (imports rose nearly tenfold between 2021 and 2024). Four different systems, four different regulatory histories, and the access pattern that emerged in each is essentially identical.
Three forces explain the convergence:
- Patient density. Medical cannabis patients are a relatively small, geographically scattered population. Building physical specialty MMJ clinics close enough to serve every patient is uneconomic and ultimately, the people will not choose to drive to a clinic and wait in line if they can schedule an appointment and speak with the MMJ doctor by video or telephone. Telehealth solved the distribution problem before traditional healthcare even attempted it.
- Stigma. Patient surveys in both Germany and the UK consistently show a preference for private telemedicine visits over walking into a visible specialty clinic. The privacy of telehealth is itself a feature. Although medical cannabis has become legal, there still seems to be a confusing stigma behind cannabis.
- Specialty concentration. In every market, a small number of physicians prescribe a disproportionate share of medical cannabis. UK Freedom of Information data showed that just 10 doctors wrote 52% of all medical cannabis prescriptions issued between 2019 and early 2025. Telehealth is truly the only way that a small pool of specialists can reach a national patient base.
The First Regulatory Backlash Has Already Begun
The same model is now drawing its first serious pushback. In October 2025, Germany’s Federal Cabinet approved draft amendments to the MedCanG that would require an in-person consultation before any first cannabis prescription, restrict mail-order dispensing, and limit follow-up telemedicine to patients who have had an in-person visit within the previous four calendar quarters. The German Health Minister cited a roughly 400% surge in cannabis imports as evidence of potential misuse. Industry groups responded that the dependency profile of medical cannabis is far lower than that of opioids or Z-drugs already routinely prescribed for the same medical conditions.
The amendments are scheduled for second and third Bundestag readings in spring 2026 (the first reading took place on December 18, 2025). If they pass in their current form, Germany will set a precedent that other EU member states are likely to study closely. Australia’s Therapeutic Goods Administration is preparing similar reforms after a public consultation on tightening telehealth-driven cannabis prescribing closed in late 2025. The US, where pandemic-era telehealth flexibilities for controlled-substance prescribing have been repeatedly extended, is heading toward its own version of the same debate.
What This Means for Markets That Have Not Legalized Yet
For African markets watching this story unfold (Lesotho became the first African nation to license medical cannabis cultivation in 2017 and is now an export player in the global supply chain. South Africa is building out its medical cannabis framework, and legalization debates continue in Ghana, Zimbabwe, and elsewhere). The lesson seems structural rather than political. Any country that develops a regulated medical cannabis market from this point forward will do so in an environment where telemedicine is already the primary access channel.
The relevant policy question has shifted drastically. It is no longer whether to permit virtual prescribing for cannabis, but what guardrails to place around it to prevent abuse. The countries that build guardrails into their first-generation legislation will avoid the kind of mid-cycle restrictions Germany is now attempting to impose retroactively, which is causing major issues.
The Verdict From Four Major Markets
Medical cannabis has turned out to be one of the largest real-world stress tests of specialty telemedicine at a national scale. Four different healthcare systems, on four different regulatory tracks, all converged on the same access model. Patients are showing up, prescription volumes followed, and the infrastructure has scaled dramatically.
Whatever the regulatory adjustments of the next eighteen months look like, the directional shift is unlikely to reverse. Once patients experience specialty care delivered through a screen in their home, the bar for in-person evaluations are basically removed permanently. In a world where technology rules and everyone has a smart phone or tablet, the digital-first specialty consultation has become the go-to option for patients.